Progesterone is Extensively Metabolized in Osteoblasts: Implications for Progesterone Action on Bone

Abstract

The effect of progestogens on bone is controversial with some studies suggesting an anabolic action while others show no effect. Prereceptor metabolism via localized expression of specific enzymes may have major impact on progesterone action in bone and may explain some of the discrepancies between studies. We therefore investigated the metabolism of progesterone in primary cultures of human osteoblasts and MG-63 osteoblastic cells. Osteoblasts and MG-63 cells were incubated with 4-¹⁴C-progesterone tracer and 50 nM unlabeled progesterone, and magnitude and pattern of progesterone metabolism were determined by two-dimensional thin-layer chromatography. Conventional and Taqman real-time PCR analysis were used to assess expression of progesterone metabolizing enzymes. In both types of cells the two major metabolic products of progesterone were 20 α-dihydroprogesterone and 5 α-dihydroprogesterone, but conversion to 3 α, 5 α- and 3 β, 5 α-tetrahydroprogesterone was also detected. This activity was concomitant with expression of mRNAs for the enzymes AKR1C1, 5 α-reductase type 1 and AKR1C2, and 3 β-HSD type 1 and 3-hydroxysteroid epimerase. In MG-63 cells progesterone metabolism was largely mediated via 5 α-reductase. In primary osteoblasts progesterone metabolism was unaffected by treatment with dexamethasone or estradiol, but in MG-63 cells dexamethasone pretreatment increased 5 α-reductase activity. Progesterone is subject to extensive intracellular inactivation in human osteoblasts, with potential attenuation of local progesterone receptor responses. Conversely, osteoblasts have the capacity to convert progestogens to metabolites reported to have anabolic actions through the estrogen receptor.

Key words

progesterone metabolites - osteoblast - MG-63 osteosarcoma cells - 5 α-reductase - dexamethasone

References

• 1 Compston JE. Sex steroids and bone.  Physiol Rev. 2001;  81 419-447
• 2 Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.  Am J Med. 1991;  90 171-178
• 3 Selby PL, Peacock M, Barkworth SA, Brown WB, Taylor GA. Early effects of ethinyloestradiol and norethisterone treatment in post-menopausal women on bone resorption and calcium regulating hormones.  Clin Sci (Lond). 1985;  69 265-271
• 4 Prior JC, Vigna YM, Barr SI, Rexworthy C, Lentle BC. Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances.  Am J Med. 1994;  96 521-530
• 5 Christiansen C, Riis BJ, Nilas L, Rodbro P, Deftos L. Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis.  Lancet. 1985;  2 800-801
• 6 Adachi JD, Sargeant EJ, Sagle MA, Lamont D, Fawcett PD, Bensen WG, MacQueen M, Nazir DJ, Goldsmith CH. A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy.  Br J Obstet Gynaecol. 1997;  104 64-70
• 7 Prior JC. Progesterone as a bone-trophic hormone.  Endocr Rev. 1990;  11 386-398
• 8 Ishida Y, Heersche JN. Progesterone- and dexamethasone-dependent osteoprogenitors in bone cell populations derived from rat vertebrae are different and distinct.  Endocrinology. 1999;  140 3210-3218
• 9 Tremollieres FA, Strong DD, Baylink DJ, Mohan S. Progesterone and promegestone stimulate human bone cell proliferation and insulin-like growth factor-2 production.  Acta Endocrinol (Copenh). 1992;  126 329-337
• 10 Canalis E. Effect of hormones and growth factors on alkaline phosphatase activity and collagen synthesis in cultured rat calvariae.  Metabolism. 1983;  32 14-20
• 11 Ishida Y, Heersche JN. Progesterone stimulates proliferation and differentiation of osteoprogenitor cells in bone cell populations derived from adult female but not from adult male rats.  Bone. 1997;  20 17-25
• 12 Luo XH, Liao EY. Progesterone differentially regulates the membrane-type matrix metalloproteinase-1 (MT1-MMP) compartment of proMMP-2 activation in MG-63 cells.  Horm Metab Res. 2001;  33 383-388
• 13 Luo XH, Liao EY, Su X. Progesterone upregulates TGF-b isoforms (b1, b2, and b3) expression in normal human osteoblast-like cells.  Calcif Tissue Int. 2002;  71 329-334
• 14 Scheven BA, Damen CA, Hamilton NJ, Verhaar HJ, Duursma SA. Stimulatory effects of estrogen and progesterone on proliferation and differentiation of normal human osteoblast-like cells in vitro.  Biochem Biophys Res Commun. 1992;  186 54-60
• 15 Canalis E, Raisz LG. Effect of sex steroids on bone collagen synthesis in vitro.  Calcif Tissue Res. 1978;  25 105-110
• 16 Quinkler M, Diederich S, Bahr V, Oelkers W. The role of progesterone metabolism and androgen synthesis in renal blood pressure regulation.  Horm Metab Res. 2004;  36 381-386
• 17 Quinkler M, Johanssen S, Grossmann C, Bahr V, Muller M, Oelkers W, Diederich S. Progesterone metabolism in the human kidney and inhibition of 11beta- hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites.  J Clin Endocrinol Metab. 1999;  84 4165-4171
• 18 Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM. Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure.  J Bone Miner Res. 2002;  17 979-986
• 19 Cooper MS, Blumsohn A, Goddard PE, Bartlett WA, Shackleton CH, Eastell R, Hewison M, Stewart PM. 11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone.  J Clin Endocrinol Metab. 2003;  88 3874-3877
• 20 Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity–a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5.  J Endocrinol. 2004;  183 331-342
• 21 Enriquez J, Lemus AE, Chimal-Monroy J, Arzate H, Garcia AG, Herrero B, Larrea F, Perez-Palacios G. The effects of synthetic 19-norprogestins on osteoblastic cell function are mediated by their non-phenolic reduced metabolites.  J Endocrinol. 2007;  193 493-504
• 22 Hayami T, Zhang Q, Kapila Y, Kapila S. Dexamethasone's enhancement of osteoblastic markers in human periodontal ligament cells is associated with inhibition of collagenase expression.  Bone. 2007;  40 93-104
• 23 Rao LG, Murray TM, Wylie JN, MacBroom RJ, Sutherland MK. Long-term culture in dexamethasone unmasks an abnormal phenotype in osteoblasts isolated from osteoporotic subjects.  J Endocrinol Invest. 2005;  28 919-927
• 24 Eijken M, Hewison M, Cooper MS, Jong FH de, Chiba H, Stewart PM, Uitterlinden AG, Pols HA, Leeuwen JP van. 11beta-Hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation.  Mol Endocrinol. 2005;  19 621-631
• 25 Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density.  BJOG. 2001;  108 1214-1221
• 26 Souza MJ De, Miller BE, Sequenzia LC, Luciano AA, Ulreich S, Stier S, Prestwood K, Lasley BL. Bone health is not affected by luteal phase abnormalities and decreased ovarian progesterone production in female runners.  J Clin Endocrinol Metab. 1997;  82 2867-2876
• 27 Waller K, Reim J, Fenster L, Swan SH, Brumback B, Windham GC, Lasley B, Ettinger B, Marcus R. Bone mass and subtle abnormalities in ovulatory function in healthy women.  J Clin Endocrinol Metab. 1996;  81 663-668
• 28 Azizi G, Hansen A, Prestwood KM. Effect of micronized progesterone on bone turnover in postmenopausal women on estrogen replacement therapy.  Endocr Res. 2003;  29 133-140
• 29 Blanchette S, Marceau P, Biron S, Brochu G, Tchernof A. Circulating progesterone and obesity in men.  Horm Metab Res. 2006;  38 330-335
• 30 Ishida Y, Killinger DW, Khalil MW, Yang K, Strutt B, Heersche JN. Expression of steroid-converting enzymes in osteoblasts derived from rat vertebrae.  Osteoporos Int. 2002;  13 235-240
• 31 Eyre LJ, Bland R, Bujalska IJ, Sheppard MC, Stewart PM, Hewison M. Characterization of aromatase and 17 beta-hydroxysteroid dehydrogenase expression in rat osteoblastic cells.  J Bone Miner Res. 1998;  13 996-1004
• 32 Issa S, Schnabel D, Feix M, Wolf L, Schaefer HE, Russell DW, Schweikert HU. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.  J Clin Endocrinol Metab. 2002;  87 5401-5407
• 33 Feix M, Wolf L, Schweikert H-U. Distribution of 17beta-hydroxysteroid dehydrogenase in human osteoblast-like cells.  Mol Cell Endocrin. 2001;  171 163-164
• 34 Kuwano Y, Fujikawa H, Watanabe A, Shimodaira K, Sekizawa A, Saito H, Yanaihara T. 3Beta-hydroxysteroid dehydrogenase activity in human osteoblast- like cells.  Endocr J. 1997;  44 847-853
• 35 Bruch HR, Wolf L, Budde R, Romalo G, Schweikert HU. Androstenedione metabolism in cultured human osteoblast-like cells.  J Clin Endocrinol Metab. 1992;  75 101-105
• 36 Wei LL, Leach MW, Miner RS, Demers LM. Evidence for progesterone receptors in human osteoblast-like cells.  Biochem Biophys Res Commun. 1993;  195 525-532
• 37 Mac NP, Loughrey HC. Progesterone receptor A and B isoform expression in human osteoblasts.  Calcif Tissue Int. 1998;  63 39-46
• 38 Quinkler M, Meyer B, Bumke-Vogt C, Grossmann C, Gruber U, Oelkers W, Diederich S, Bahr V. Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor.  Eur J Endocrinol. 2002;  146 789-799
• 39 Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T, Sasano H. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.  J Clin Endocrinol Metab. 2001;  86 2250-2257
• 40 Weiler PJ, Wiebe JP. Plasma membrane receptors for the cancer-regulating progesterone metabolites, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-4-pregnen-20-one in MCF-7 breast cancer cells.  Biochem Biophys Res Commun. 2000;  272 731-737
• 41 Wiebe JP, Muzia D, Hu J, Szwajcer D, Hill SA, Seachrist JL. The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion.  Cancer Research. 2000;  60 936-943
• 42 Wiebe JP, Lewis MJ. Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells.  BMC Cancer. 2003;  3 ((9)) 1-15

Correspondence